Bispecific Antibody AMV564 Active in Relapsed and Refractory AML
Treatment with the CD33/CD3 bivalent, bispecific antibody AMV564 demonstrated clinical activity in patients with relapsed and refractory acute myeloid leukemia (AML) with a tolerable...
Higher-Dose Daunorubicin No More Effective Than Lower Doses in AML
Escalating daunorubicin doses from 60 mg/m2 to 90 mg/m2 in a 7+3 induction regimen consisting of daunorubicin and cytarabine did not increase response rates...
FDA Approves IDH Inhibitor for Patients with AML
The U.S. Food and Drug Administration (FDA) has approved ivosidenib as the first IDH1 inhibitor for patients with relapsed or refractory acute myeloid leukemia...
Preliminary Results Show Flotetuzumab Well-Tolerated and Effective in Relapsed/Refractory AML and MDS
In early results from a phase I trial presented at the 2017 ASH Annual Meeting, researchers reported that the bispecific antibody flotetuzumab demonstrated anti-leukemic...
Treating MRD With Azacitidine in Patients With High-Risk AML and MDS
For 58 percent of patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) at high risk for relapse, treatment of minimal residual disease...
Early-Phase Study Finds Duvelisib Active in Variety of Advanced Hematologic Malignancies
The oral phosphoinositide 3-kinase (PI3K) dual inhibitor duvelisib appeared to be active and tolerable at a range of doses and across a variety of...
Single-Agent Vadastuximab Talirine Active, Tolerable in AML
In a first-in-human study of patients with CD33-positive acute myeloid leukemia (AML), treatment with single-agent vadastuximab talirine (a CD33-targeted antibody-drug conjugate) resulted in a...
Two Versus Three Cycles of Consolidation Therapy for Patients With AML
Patients with core-binding factor acute myeloid leukemia (CBF-AML) who received only two cycles of consolidation chemotherapy experienced similar rates of relapse-free survival (RFS) and...
FLT3 Inhibitors in Older Patients with Acute Myeloid Leukemia: More Questions Than Answers?
Acute myeloid leukemia (AML) affects primarily older adults (with a median age of 67 years at diagnosis), and management of the disease in this...
Current Issue
August 2020 Volume 6, Issue 10
This issue looks at the rapid expansion of telemedicine, explores access to leukemia treatment in Brazil, and more.
